A Risk-Based Approach for Managing Affinity Resin Contaminations

References

1. 1.↵
   1. Murphy M.,
   2. Bell B. L.,
   3. Moshi J.,
   4. Grassi R.,
   5. Forng R.-Y.,
   6. Salaman A.,
   7. Jordi P. W.,
   8. Zaidi S.,
   9. Goodnight M.,
   10. Paul M.,
   11. Keller A.,
   12. Carpenter B.,
   13. Hearty U.,
   14. Willison-Parry D.

   Microbiological Control for Affinity Capture Chromatography Processing: An Industry Perspective. PDA J. Pharm. Sci. Technol. 2018, 72 (2), 213–221.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Suvarna K.,
   2. Lolas A.,
   3. Hughes P.,
   4. Friedman R. L.

   Case Studies of Microbial Contamination in Biologic Product Manufacturing. Am. Pharm. Rev. 2011, 14 (1), 50–56.

   OpenUrl
3. 3.↵
   1. Rathore A.,
   2. Pathak M.,
   3. Ma G.,
   4. Bracewell D. G.

   Re-Use of Protein A Resin: Fouling and Economics. BioPharm Int. 2015, 28 (3), 28–33.

   OpenUrl
4. 4.↵
   1. Boulet-Audet M.,
   2. Byrne B.,
   3. Kazarian S. G.

   Cleaning-in-Place of Immunoaffinity Resins Monitored by in Situ ATR-FTIR Spectroscopy. Anal. Bioanal. Chem. 2015, 407 (23), 7111–7122.

   OpenUrl
5. 5.↵
   Efficient Cleaning-in-Place Methods for Protein-Based Antibody Affinity Chromatography Resins. https://cdn.cytivalifesciences.com/api/public/content/digi-24266-original (accessed November 19, 2022).
6. 6.↵
   Chemical Disinfectants and Antiseptics - Quantitative Nonporous Surface Test for the Evaluation of Bactericidal and/or Fungicidal Activity of Chemical Disinfectants Used in Food, Industrial, Domestic and Institutional Areas - Test Method and Requirements Without Mechanical Action (Phase 2, Step 2). ICS 11.080.20. International Classification for Standards, 2015.
7. 7.↵
   US Pharmacopeial Convention, General Chapter <1116> Microbiological Evaluation of Clean Rooms and Other Controlled Environments. In USP 33—NF 28, USP: Rockville, MD, 2010.
8. 8.↵
   International Conference for Harmonisation, Quality Guideline Q9(R1) Quality Risk Management. ICH: Geneva, 2021. https://database.ich.org/sites/default/files/ICH_Q9-R1_Document_Step2_Guideline_2021_1118.pdf (accessed November 19, 2022).
9. 9.↵
   World Health Organization. Annex 7: Application of Hazard Analysis and Critical Control Point (HACCP) Methodology to Pharmaceuticals; WHO Technical Report Series No. 908; WHO: Geneva, 2003.
10. 10.↵
    U.S. Food and Drug Administration, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. Center for Biologics Evaluation and Research. Department of Health and Human Services: Rockville, MD, 2004.
11. 11.↵
    Parenteral Drug Association Inc. PDA Technical Report No. 69: Bioburden and Biofilm Management in Pharmaceutical Manufacturing Operations; Bethesda, MD, 2015.
12. 12.↵
    1. Waldron K.

    Integration of Risk Management Principles into the Quality System: Risk-Based Impact Assessment. J. GXP Compliance 2013, 17 (2).
13. 13.↵
    Impact of Sporicidal Agent on MabSelect SuRe Protein A Resin Lifetime. https://cdn.cytivalifesciences.com/api/public/content/digi-18576-original (accessed November 19, 2022)
14. 14.↵
    ASTM International, ASTM G31-21 Standard Guide for Laboratory Immersion Corrosion Testing of Metals. ASTM: West Conshohocken, PA, 2021.
15. 15.↵
    ASTM International, ASTM D543-21 Standard Practices for Evaluating the Resistance of Plastics to Chemical Reagents. ASTM, West Conshohocken, PA, 2021.
16. 16.↵
    1. Swaminathan V.

    Commonly Used Materials and 316L Properties in the Biotech, Pharmaceutical Industries. https://ispe.org/sites/default/files/membership/affiliates-chapters/san-diego/techical-pharma-papers/san-diego-common-use-mats-316l-props.pdf (accessed November 19, 2022).
17. 17.↵
    1. Holt J.,
    2. Atkins K.,
    3. Shapcott S.

    Corrosion Testing for Risk Reduction in Chemical Process Development Safe and Reliable Introduction of New Process Technologies. Johnson Matthey Technol. Rev. 2023, 67 (1).
18. 18.↵
    Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community Code Relating to Medicinal Products for Human Use (Text with EEA Relevance). https://www.legislation.gov.uk/eudr/2003/63/adopted (accessed November 19, 2022).
19. 19.↵
    U.S. Food and Drug Administration, 21 CFR Part 211–Current Good Manufacturing Practice for Finished Pharmaceuticals. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211 (accessed November 19, 2022).
20. 20.↵
    International Conference for Harmonisation, ICH Guideline Q10 on Pharmaceutical Quality System. ICH guideline Q10 on pharmaceutical quality system—Step 5. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human_en.pdf (accessed November 19, 2022).